Matthew Vincent Dolan, EVP Strategy and Corporate Development at DEXCOM INC (DXCM), sold 4,846 shares at $126.58 ($613K) on 2024-05-15, disclosed to the SEC on 2024-05-16.
Scheduled sale ($613k) by EVP Strategy and Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $126.58 | 2,423 | $307K | 50.0% |
| 2 | $126.58 | 2,423 | $307K | 50.0% |
| Total | $126.58 avg | 4,846 | $613K | 100% |
| Filing → |
| DXCM | SELL | 2024-03-19 | $1.1M | — | Filing → |
| DXCM | SELL | 2024-03-14 | $1.8M | — | Filing → |
| DXCM | SELL | 2023-09-01 | $6K | — | Filing → |